Veracyte (NASDAQ: VCYT) reported Q4 EPS of ($0.39), $0.30 worse than the analyst estimate of ($0.09). Revenue for the quarter came in at $98.2 million versus the consensus estimate of $91.29 million.

GUIDANCE:

Veracyte sees FY2024 revenue of $394-402 million, versus the consensus of $392.7 million.

For earnings history and earnings-related data on Veracyte (VCYT) click here.